Bruker Corporation

Bruker Corporation(BRKR)股票分析

$56.540

+0.956 (+1.69%)收盘时

Loading chart…
最高
57.010
开盘
54.970
成交量加权均价
56.00
成交量
2.11M
市值
9.72B
最低
54.440
成交额
117.95M
企业价值/息税折旧摊销前利润(TTM)
17.12

Bruker Corporation is a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic solutions. The Company's segments include Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST). Its BSI segment designs, manufactures and distributes life science tools based on magnetic resonance technology and offers automated laboratory research and development solutions in chemical research fields. Its BSI CALID segment designs, manufactures and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. BSI NANO designs, manufactures and distributes advanced x-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and others.

AI 分析 of Bruker Corporation (BRKR)

持有

Bruker Corp is currently priced at $58.84, which is below several analyst price targets, including $70 from Barclays and $72 from Guggenheim. However, the stock has an RSI of 36.731, indicating it is in the oversold territory, which could signal a potential rebound. The recent 5-day change of -6.96% and a significant loss of $65.3 million in Q2 raises concerns about profitability. Therefore, while there are positive catalysts like increased hedge fund ownership and a partnership in superconductors, the risks associated with recent performance and market sentiment suggest holding rather than buying at this time.

分析师评级(14)

-7.71% 下跌空间
持有
2 买入
10 持有
2 卖出
当前: 56.54
最低
40.00
平均
52.18
最高
60.00

Barclays

2026-10-07

目标价

$70

增持

Guggenheim

2026-10-01

目标价

$72

买入

Leerink

2026-09-29

目标价

$80

跑赢大盘

UBS

2026-09-09

目标价

$65

中性

TD Cowen

2026-07-15

目标价

$60

持有

估值指标

Bruker Corporation(BRKR)当前预期市盈率为 13.83,5 年平均预期市盈率为 23.50。

预期市盈率

低估
5 年均值 P/E
23.50
当前P/E
13.83
高估
29.60
低估
17.40

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
17.56
当前EV/EBITDA
17.12
高估
21.13
低估
13.98

预期市销率

合理
5 年均值 P/S
2.90
当前P/S
2.29
高估
3.81
低估
1.99

Alphio AI 对 BRKR 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%BRKR

$53.26

情景价格

基

基准

基准 · 50%BRKR

$44.40

情景价格

悲

悲观

悲观 · 25%BRKR

$41.00

情景价格

持有 BRKR 的大户

E

Edmond de Rothschild Asset Management (France)

+ 持有BRKR

+9.07%

3个月收益率

B

Becker Capital Management Inc

+ 持有BRKR

+5.59%

3个月收益率

S

Snyder Capital Management, L.P.

+ 持有BRKR

+4.53%

3个月收益率

C

Cornerstone Investment Partners, LLC

+ 持有BRKR

+3.97%

3个月收益率

P

Pallas Capital Advisors LLC

+ 持有BRKR

+2.32%

3个月收益率

O

Orbis Investment Management Limited

+ 持有BRKR

+0.51%

3个月收益率

BRKR 常见问题 —— 由 Alphio AI 解答

Bruker Corporation is a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic solutions. The Company's segments include Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST). Its BSI segment designs, manufactures and distributes life science tools based on magnetic resonance technology and offers automated laboratory research and development solutions in chemical research fields. Its BSI CALID segment designs, manufactures and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. BSI NANO designs, manufactures and distributes advanced x-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and others. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Bruker Corp is currently priced at $58.84, which is below several analyst price targets, including $70 from Barclays and $72 from Guggenheim. However, the stock has an RSI of 36.731, indicating it is in the oversold territory, which could signal a potential rebound. The recent 5-day change of -6.96% and a significant loss of $65.3 million in Q2 raises concerns about profitability. Therefore, while there are positive catalysts like increased hedge fund ownership and a partnership in superconductors, the risks associated with recent performance and market sentiment suggest holding rather than buying at this time.

14 analysts cover BRKR: 2 rate it Buy, 10 Hold and 2 Sell. The average price target is 52.18.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易